Chiltern Announces New Offices and Expansion Plans in Asia Pacific
Chiltern International Limited (Chiltern), a global contract research organization (CRO), has announced its expansion plans in Asia Pacific.
Chiltern has established two new offices and launched operations in Australia and Singapore – with Singapore acting as the hub for its operations in Southeast Asia. This builds upon Chiltern’s operation in India.
Chiltern is also in the process of forming a company and establishing operations in China. Chiltern’s Asia Pacific operations will be led by Umakanta Sahoo, Executive Director, Asia Pacific. Commenting on the growth, “Chiltern’s expansion will provide a platform from which global pharmaceutical and biotech Sponsors can expand their geographic reach and enhance patient recruitment in the Asia Pacific region,” stated Dr. Sahoo.
Glenn Kerkhof, Chiltern CEO, stated, “Asia Pacific is one of the foremost emerging markets in our industry. With the current expansion of pharmaceutical R & D needs into the Asia Pacific region, Chiltern is positioned to meet the needs this growth entails. We are very pleased to provide our clients with access to this market.”
Chiltern is currently recruiting clinical staff and plans to grow its workforce in the Asia Pacific region to 70 by the end of 2010.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
